Table 3.
Ang1, Ang2, and VEGF levels in control group and VHD patients.
| Parameter | Control (n=20) | VHD with NYHA I/II (n=30) | VHD with NYHA III/IV (n=12) | P-valuea | P-valueb |
|---|---|---|---|---|---|
| Ang1 (pg/mL) | 2842.96±769.51 | 7841.771±2927.14 | 3602.88±769.35 | 0.151 | 0.857 |
| Ang2 (pg/mL) | 1736.70±95.69 | 1317.01±120.36 | 1567.81±189.27 | 0.017 | 0.485 |
| VEGF (pg/mL) | 109.58±17.92 | 121.02±20.87 | 88.34±44.70 | 0.686 | 0.531 |
The results are expressed as means±standard deviation. Statistical difference between the groups was evaluated using one-way analysis of variance P-valuea: NYHA I/II vs. control P-valueb: NYHA III/IV vs. control Ang=angiopoietin; NYHA=New York Heart Association; VEGF=vascular endothelial growth factor; VHD=valvular heart disease